CVS Health Earnings Reports

CVS Health reported Q4 2024 revenue of $97.71 billion, up 4.2% YoY, but experienced a decline in operating income and net income due to pressures in the Health Care Benefits segment. GAAP EPS fell to $1.30 from $1.58, and Adjusted EPS dropped to $1.19 from $2.12.

CVS Health's total revenues for the third quarter increased by 6.3% to $95.4 billion. GAAP diluted EPS was $0.07, and adjusted EPS was $1.09. The results were impacted by charges related to premium deficiency reserves in the Health Care Benefits segment.

CVS Health reported a 2.6% increase in total revenues for the second quarter of 2024, reaching $91.2 billion. However, GAAP diluted EPS decreased to $1.41, and Adjusted EPS decreased to $1.83, primarily due to declines in the Health Care Benefits segment. The company has revised its full-year 2024 guidance to reflect continued pressure in the Health Care Benefits segment, partially offset by strong performance in the Health Services and Pharmacy & Consumer Wellness segments.

CVS Health's Q1 2024 results showed revenue growth but a decline in profitability due to increased Medicare utilization. The company has revised its full-year guidance to reflect these challenges.

CVS Health's Q4 2023 total revenues increased to $93.8 billion, up 11.9% compared to prior year. GAAP diluted EPS was $1.58 and Adjusted EPS was $2.12.

CVS Health reported a 10.6% increase in total revenues, reaching $89.8 billion, driven by growth across all segments. GAAP diluted EPS was reported at $1.75, and adjusted EPS at $2.21. The company is adapting to changing consumer needs by connecting care delivery capabilities and broadening access to affordable health and wellness services.

CVS Health reported a 10.3% increase in total revenues to $88.9 billion for Q2 2023, driven by growth across all segments. GAAP diluted EPS was $1.48, and adjusted EPS was $2.21. The company is executing its strategy to expand access to health services and strengthen consumer engagement.

CVS Health reported a strong first quarter with total revenues increasing by 11.0% to $85.3 billion. GAAP diluted EPS was $1.65, and Adjusted EPS was $2.20. The company generated $7.4 billion in cash flow from operations and completed the acquisitions of Signify Health and Oak Street Health.

CVS Health's Q4 2022 results showed a total revenue increase of 9.5% to $83.8 billion and a GAAP diluted EPS of $1.75. The company's performance was driven by growth across all segments.

CVS Health reported a revenue increase of 10.0% to $81.2 billion. However, the company experienced a GAAP loss per share of $(2.60) due to significant charges, including $5.2 billion for opioid litigation and $2.5 billion related to the Omnicare long-term care business. Despite the loss, the adjusted EPS was $2.09.

CVS Health's total revenues increased to $80.6 billion, up 11.0% compared to prior year. GAAP diluted EPS was $2.23 and Adjusted EPS was $2.40. The company raised its full-year 2022 GAAP diluted EPS guidance range to $7.23 to $7.43 from $6.93 to $7.13 and raised its full-year 2022 Adjusted EPS guidance range to $8.40 to $8.60 from $8.20 to $8.40. The company also raised its full-year 2022 cash flow from operations guidance range to $12.5 billion to $13.5 billion from $12.0 billion to $13.0 billion.

CVS Health reported a strong first quarter with total revenues increasing by 11.2% to $76.8 billion. GAAP diluted EPS was $1.74, and adjusted EPS was $2.22. The company generated $3.6 billion in cash flow from operations and raised its full-year adjusted EPS guidance.

CVS Health's Q4 2021 total revenues increased to $76.6 billion, up 10.1% compared to the prior year. GAAP diluted EPS was $0.98, and adjusted EPS was $1.98. The company administered over 8 million COVID-19 tests and 20 million vaccines in Q4 2021.

CVS Health reported strong Q3 2021 results with total revenues increasing to $73.8 billion, GAAP diluted EPS of $1.20, and adjusted EPS of $1.97.

CVS Health announced strong Q2 2021 results with total revenues increasing to $72.6 billion, up 11.1% compared to the prior year. The company raised its full year EPS and cash flow from operations guidance.

CVS Health announced strong Q1 results, with total revenues increasing to $69.1 billion, a 3.5% increase compared to the prior year. GAAP diluted EPS was $1.68, up 9.8% year-over-year, and adjusted EPS was $2.04, reflecting a 6.8% increase. The company generated a cash flow from operations of $2.9 billion and raised its full-year EPS guidance.

CVS Health's Q4 2020 results reflected COVID-19 impacts and related investments. Full year total revenues increased to $268.7 billion, up 4.6% compared to prior year. The company utilized its capabilities and community presence for COVID-19 testing and vaccine administration.

CVS Health reported a 3.5% increase in total revenues to $67.1 billion, GAAP diluted earnings per share of $0.93, and adjusted EPS of $1.66. The company raised its full-year 2020 EPS and cash flow from operations guidance ranges.

CVS Health reported a 3.0% increase in total revenues, reaching $65.3 billion. GAAP operating income increased by 40.5% to $4.7 billion, and adjusted operating income increased by 32.2% to $5.3 billion. GAAP diluted earnings per share was $2.26, and adjusted EPS was $2.64.

CVS Health reported an 8.3% increase in total revenues to $66.8 billion and a 28.6% increase in GAAP operating income to $3.5 billion. Adjusted EPS was $1.91, and the company generated $3.3 billion in cash flow from operations. 2020 full year EPS guidance remains unchanged.

CVS Health's Q4 2019 revenues increased by 22.9% to $66.9 billion, GAAP operating income increased to $3.0 billion, and adjusted operating income increased by 1.3% to $3.8 billion. GAAP diluted earnings per share from continuing operations were $1.33, and adjusted EPS was $1.73. The company's performance reflects strong financial and operational execution and a successful first year of integrating the Aetna business.